Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes

Vaccine

Volumn 32, Issue 32, 2014, Pages 4104-4110

  De Amicis, Karine M ^a   Freschi de Barros, Samar ^a   Alencar, Raquel E ^a   Postól, Edilberto ^a   Martins, Carlo de Oliveira ^a   Arcuri, Helen Andrade ^a   Goulart, Cibelly ^b   Kalil, Jorge ^a   Guilherme, Luiza ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Immune response; Immunization coverage; Rheumatic fever; Streptococcus pyogenes; Vaccine

Indexed keywords

BACTERIUM ANTIBODY; CROSS REACTING ANTIBODY; M PROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; STREPTINCOR VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GROUP A STREPTOCOCCAL INFECTION; HEART VALVE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOREACTIVITY; IN VITRO STUDY; MICROSCOPY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OPSONIZATION; PERITONEUM CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; STREPTOCOCCUS PYOGENES; WESTERN BLOTTING; ANIMAL; AUTOIMMUNITY; BAGG ALBINO MOUSE; BLOOD; CROSS REACTION; IMMUNOLOGY; MITRAL VALVE; PHAGOCYTOSIS; STREPTOCOCCAL INFECTIONS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; AUTOIMMUNITY; CROSS REACTIONS; HUMANS; MICE; MICE, INBRED BALB C; MITRAL VALVE; PHAGOCYTOSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES;

EID: 84902553232     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.043     Document Type: Article

References (34)

1. Narula J., Virmani R., Reddy K.S., Tandon R. Rheumatic fever 1999, Washington, DC, American Registry of Pathology.
2. Guilherme L., Köhler K.F., Postol E., Genes K.J. Autoimmunity and pathogenesis of rheumatic heart disease. Ann Pediatr Cardiol 2011, 4:13-21.
3. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005, 5:685-694.
4. Barbosa P.J.B., Müller R.E., Latado A.L., Achutti A.C., Ramos A.I.O., Weksler C., et al. Diretrizes Brasileiras para Diagnóstico, Tratamento e Prevenção da Febre Reumática da Sociedade Brasileira de Cardiologia, da Sociedade Brasileira de Pediatria e da Sociedade Brasileira de Reumatologia. Arquivos Brasileiros de Cardiologia 2009, 93(3 Suppl. 4):1-18.
5. Tartof S.Y., Reis J.N., Andrade A.N., Ramos R.T., Reis M.G., Riley L.W. Factors associated with Group A streptococcus emm type diversification in a large urban setting in Brazil: a cross-sectional study. BMC Infect Dis 2010, 10:327.
6. Smeesters P.R., McMillan D.J., Sriprakash K.S. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010, 18:275-282.
7. Bisno A.L., Brito M.O., Collins C.M. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003, 3:191-200.
8. McMillan D.J., Drèze P.-A., Vu T., Bessen D.E., Guglielmini J., Steer A.C., et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Authors Clin Microbiol Infec 2012, 5:222-229.
9. Guilherme L., Kalil J., Cunningham M. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity 2006, 39:31-39.
10. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000, 13:470-511.
11. Guilherme L., Cunha-Neto E., Coelho V., Snitcowsky R., Pomerantzeff P.M., Assis R.V., et al. Human heart-infiltrating T-cell clones from rheumatic heart disease patients recognize both streptococcal and cardiac proteins. Circulation 1995, 92:415-420.
12. Steer A.C., Law I., Matatolu L., Beall B.W., Carapetis J.R. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 2009, 9:611-616.
13. Smeesters P.R., McMillan D.J., Sriprakash K.S., Georgousakis M.M. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines. Expert Rev Vaccines 2009, 8:1705-1720.
14. Guilherme L., Freschi de Barros S., Tanaka A.C., Ribeiro Castro M., Kalil J. S. Pyogenes infections and its sequelae. An update on Glomerulopathies - Clinical and Treatment Aspects 2011, InTech. S.S. Prabhakar (Ed.).
15. Shulman S.T., Tanz R.R., Dale J.B., Beall B., Kabat W., Kabat K., et al. Seven-year surveillance of North American pediatric group a streptococcal pharyngitis isolates. Clin Infect Dis 2009, 49:78-84.
16. Smeesters P.R., Vergison A., Campos D., de Aguiar E., Miendje Deyi V.Y., van Melderen L. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS One 2006, 1:e10.
17. McGregor K.F., Spratt B.G., Kalia A., Bennett A., Bilek N., Beall B., et al. Multilocus sequence typing of Streptococcus pyogenes representing most known emm types and distinctions among subpopulation genetic structures. J Bacteriol 2004, 186:4285-4294.
18. Bessen D.E., Carapetis J.R., Beall B., Katz R., Hibble M., Currie B.J., et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 2000, 182:1109-1116.
19. McMillan D.J., Drèze P.A., Vu T., Bessen D.E., Guglielmini J., Steer A.C., et al. Updated model of group A Streptococcus M proteins based on a comprehensive worldwide study. Clin Microbiol Infect 2013, 19:E222-E229.
20. Smeesters P.R., Mardulyn P., Vergison A., Leplae R., van Melderen L. Genetic diversity of Group A Streptococcus M protein: implications for typing and vaccine development. Vaccine 2008, 26:5835-5842.
21. Steer A.C., Dale J.B., Carapetis J.R. Progress toward a global group a streptococcal vaccine. Pediatr Infect Dis J 2013, 32:180-182.
22. Dale J.B., Fischetti V.A., Carapetis J.R., Steer A.C., Sow S., Kumar R., et al. Group A streptococcal vaccines: paving a path for accelerated development. Vaccine 2013, 31(Suppl. 2):B216-B222.
23. McNeil S.A., Halperin S.A., Langley J.M., Smith B., Warren A., Sharratt G.P., et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005, 41:1114-1122.
24. Steer A.C., Batzloff M.R., Mulholland K., Carapetis J.R. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 2009, 22:544-552.
25. Guilherme L., Faé K.C., Higa F., Chaves L., Oshiro S.E., Freschi de Barros S., et al. Towards a vaccine against rheumatic fever. Clin Dev Immunol 2006, 13:125-132.
26. Guilherme L., Alba M.P., Ferreira F.M., Oshiro S.E., Higa F., Patarroyo M.E., et al. Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem 2011, 286:6989-6998.
27. Guilherme L., Postol E., Freschi de Barros S., Higa F., Alencar R., Lastre M., et al. A vaccine against S. pyogenes: design and experimental immune response. Methods 2009, 49:316-321.
28. Postol E., Alencar R., Higa F.T., Freschi de Barros S., Demarchi L.M., Kalil J., et al. StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. PLoS One 2013, 8:e60969.
29. Guerino M.T., Postol E., Demarchi L.M., Martins C.O., Mundel L.R., Kalil J., et al. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine 2011, 29(46):8250-8256.
30. Guilherme L., Barros S.F.d., Tanaka A.C., Castro M.C.R., Kalil J. S. pyogenes infection and it's sequelae 2011, 468. Rijeka, Croácia.
31. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
32. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979, 76:4350-4354.
33. Goulart C., Darrieux M., Rodriguez D., Pimenta F.C., Brandileone M.C., de Andrade A.L., et al. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 2011, 29:1634-1642.
34. Dale J.B., Penfound T.A., Tamboura B., Sow S.O., Nataro J.P., Tapia M., et al. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 2013, 31:1576-1581.